Humoral Hypercalcemia of Cancer

New England Journal of Medicine

Volumn 319, Issue 9, 1988, Pages 556-563

  Flier, Jeffrey S ^a   Underhill, Lisa H ^a   Broadus, Arthur E ^b   Mangin, Marguerite ^b   Ikeda, Kyoji ^b   Insogna, Karl L ^b   Weir, Eleanor C ^b   Burtis, William J ^b   Stewart, Andrew F ^b  

^a University School of Medicine ^*

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; PEPTIDE;

CANCER; HUMAN; HYPERCALCEMIA; PRIORITY JOURNAL; REVIEW;

ANIMAL; HUMAN; HYPERCALCEMIA; NEOPLASM PROTEINS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; PARATHYROID HORMONES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023677625     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198809013190906     Document Type: Review

References (79)

1. Case Records of the Massachusetts General Hospital (Case 27461). N Engl J Med 1941; 225: 789–91.
2. Burtis WJ, Wu T, Bunch C, et al. Identification of a novel 17,000-dalton parathyroid hormone–like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 1987; 262: 7151–6.
3. Moseley JM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid Hormone-Related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 1987; 84: 5048–52.
4. Stewart AF, Wu T, Goumas D, Burtis WJ, Broadus AE. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains. Biochem Biophy Res Commun 1987; 146: 672–8.
5. Strewler GJ, Stern PH, Jacobs JW. et al. Parathyroid hormone–like protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone. J Clin Invest 1987; 80: 1803–7.
6. Suva LJ, Winslow GA, Wettenhall REH, et al. A parathyroid Hormone-Related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237: 893–6.
7. Mangin M, Webb achéal. Dreyer B, et al. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 1988; 85: 597–601.
8. Mundy GR, Ibbotson KJ, D'Souza SM, Simpson EL, Jacobs JW, Martin TJ. The hypercalcemia of cancer: clinical implications and pathogenic mechanisms. N Engl J Med 1984; 310: 1718–27.
9. Rodman JS, Sherwood LM. Disorders of mineral metabolism in malignancy. In: Avioli LV, Krane SM, eds. Metabolic bone disease. Vol. 2. New York: Academic Press, 1978:577–631.
10. Godsall JW, Burtis WJ, Insogna KL, Broadus AE, Steward AF. Nephrogenous cyclic AMP, adenylate cyclase-stimulating activity, and the humoral hypercalcemia of malignancy. Recent Prog Horm Res 1986; 40: 705–50.
11. Mundy GR. The hypercalcemia of malignancy. Kidney Int 1987; 31: 142–55.
12. Broadus AE, Stewart AF. Humoral mechanisms of hypercalcemia. In: Peck WA, eds. Bone and mineral research. Vol. 2. Amsterdam: Elsevier, 1984: 311–65.
13. Zondek H, Petow H, Siebert W. Die Bedeutung der Calciumbestimmung im Blute für die Diagnose der Niereninsuffizientz. Z Klin Med 1924; 99: 129–38.
14. Gutman AB, Tyson TL. Gutman EB. Serum calcium, inorganic phosphorus and phosphatase activity in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic disease of the bones. Arch Intern Med 1936; 57: 379–413.
15. Plimpton CH, Gellhorn A. Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med 1956; 21: 750–9.
16. Connor TB, Thomas WC Jr, Howard JF. The etiology of hypercalcemia associated with lung carcinoma. J Clin Invest 1956; 35: 697–8. abstract.
17. Lafferty FW. Pseudohyperparathyroidism. Medicine (Baltimore) 1966; 45: 247–60.
18. Cramer SF, Fried L, Carter KJ. The cellular basis of metastatic bone disease in patients with lung cancer. Cancer 1981; 48: 2649–60.
19. Ralston S, Fogelman I, Gardner MD, Boyle IT. Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet 1982; 2: 903–5.
20. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978; 276: 726–8.
21. Greaves M, Ibbotson KJ, Atkins D, Martin TJ. Prostaglandins as mediators of bone resorption in renal and breast tumours. Clin Sci 1980; 58: 201–10.
22. Tashjian AH Jr. Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L. Tumor necrosis factor-α (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology 1987; 120: 2029–36.
23. Dewhirst FE, Stashenko PP, Mole JE. Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 1985; 135: 2562–8.
24. Bertolini DR. Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature 1986; 319: 516–8.
25. Gordan GS, Fitzpatrick ME, Lubich WP. Identification of osteolytic sterols in human breast cancer. Trans Assoc Am Physicians 1967; 80: 183–9.
26. Haddad JC Jr, Couranz SJ, Avioli LV. Circulating phytosterols in normal females, lactating mothers and breast cancer patients. J Clin Endocrinol Metab 1970; 30: 174–80.
27. Tashjian AH Jr. Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Res 1978; 38: 4138–41.
28. Seyberth HW, Segre GV, Morgan JL, Sweetman BJ, Potts JT Jr, Oates JA. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 1975; 293: 1278–83.
29. Brenner DE, Harvey HA, Lipton A, Demers L. A study of prostaglandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy. Cancer 1982; 49: 556–61.
30. Metz SA, McRae JR, Robertson RP. Prostaglandins as mediators of paraneoplastic syndromes: review and up-date. Metabolism 1981; 30: 299–316.
31. Powell D, Singer FR, Murray TM, Minkin C, Potts JT Jr. Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. N Engl J Med 1973; 289: 176–81.
32. Riggs BL, Arnaud CD, Reynolds JC, Smith LH. Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. J Clin Invest 1971; 50: 2079–83.
33. Benson RC Jr, Riggs BL, Pickard BM, Arnaud CD. Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. J Clin Invest 1974; 54: 175–81.
34. Hamilton JW, Hartman CR, McGregor DH, Cohn CV. Synthesis of parathyroid hormone-like peptides by a human squamous cell carcinoma. J Clin Endocrinol Metab 1977; 45: 1023–30.
35. Simpson EL, Mundy GR, D'Souza SM, Ibbotson KJ, Bockman R, Jacobs JW. Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. N Engl J Med 1983; 309: 325–30.
36. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 1980; 303: 1377–83.
37. Goltzman D, Stewart AF, Broadus AE. Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. J Clin Endocrinol Metab 1981; 53: 899–904.
38. Stewart AF, Insogna KL, Goltzman D, Broadus AE. Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimuiating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 1983; 80: 1454–8.
39. Strewler GJ, Williams RD, Nissenson RA. Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors. J Clin Invest 1983; 71: 769–74.
40. Insogna KL, Steward AF, Vignery AM-C, et al. Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology 1984; 114: 888–96.
41. Weir EC, Norrdin RE, Matus M, et al. Humoral hypercalcemia of malignancy in canine lymphosarcoma. Endocrinology 1988; 122: 602–8.
42. Ibbotson KJ, D'Souza SM, Ng KW, et al. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science 1983; 221: 1292–4.
43. Ibbotson KJ, D'Souza SM, Smith DD, Carpenter G, Mundy GR. EGF receptor antiserum inhibits bone resorbing activity produced by a rat Leydig cell tumor associated with the humoral hypercalcemia of malignancy. Endocrinology 1985; 116: 469–71.
44. Gkonos PJ, Hayes T, Burtis W, et al. Squamous carcinoma model of humoral hypercalcemia of malignancy. Endocrinology 1984; 115: 2384–90.
45. Sato K, Mimura H, Han DC, et al. Production of bone-resorbing activity and colony-stimulating activity in vivo and in vitro by a human squamous cell carcinoma associated with hypercalcemia and leukocytosis. J Clin Invest 1986; 78: 145–54.
46. Bringhurst FR, Bierer BE, Godeau F, Neyhard N, Vamer V, Segre GV, Humoral hypercalcemia of malignancy: release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells. J Clin Invest 1986; 77: 456–64.
47. Insogna KL, Weir EC, Wu TL, et al. Co-purification of transforming growth factor β-like activity with PTH-like and bone-resorbing activities from a tumor associated with humoral hypercalcemia of malignancy. Endocrinology 1987; 120: 2183–5.
48. Mundy GR, Ibbotson KJ. D'Souza SM. Tumor products and the hypercalcemia of malignancy. J Clin Invest 1985; 76: 391–4.
49. Stewart AF, Vignery A, Silverglate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982; 55: 219–27.
50. Rude RK. Sharp CF Jr, Fredericks RS, et al. Urinary and nephrogenous adenosine 3', 5'-monophosphate in the hypercalcemia of malignancy. J Clin Endocrinol Metab 1981; 52: 765–71.
51. Kukreja SC, Shemerdiak WP, Lad TE, Johnson PA. Elevate nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. J Clin Endocrinol Metab 1980; 51: 167–9.
52. McDonnell GD, Dunstan CR, Evans RA, et al. Quantitative bone histology in the hypercalcemia of malignant disease. J Clin Endocrinol Metab 1982; 55: 1066–72.
53. Strewler GJ, Wronski TJ, Halloran BP, et al. Pathogenesis of hypercalcemia in nude mice bearing a human renal carcinoma. Endocrinology 1986; 119: 303–10.
54. Ralston SH, Fogelman I, Gardner MD, Dryburgh FJ, Cowan RA, Boyle IT. Hypercalcaemia of malignancy: evidence of a non-parathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci 1984; 66: 187–91.
55. Rizzoli R, Caverzasio J, Fleisch H, Bonjour JP. Parathyroid hormone-like changes in renal calcium and phosphate reabsorption induced by Leydig cell tumor in thyroparathyroidectomized rats. Endocrinology 1986; 119: 1004–9.
56. Coombes RC, Ward MK, Greenberg PB, et al. Calcium metabolism in cancer: studies using calcium isotopes and immunoassay for parathyroid hormone and calcitonin. Cancer 1976; 38: 2111–20.
57. Horiuchi N, Caulfield MP, Fisher JE, et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987; 238: 1566–8.
58. Hulter HN, Halloran BP, Toto RD, Peterson JC. Long-term control of plasma calcitriol concentration in dogs and humans: dominant role of plasma concentration in experimental hyperparathyroidism. J Clin Invest 1985; 76: 695–702.
59. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CYC. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med 1984; 100: 1–7.
60. Rosenthal N, Insogna KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab 1985; 60: 29–33.
61. Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirusassociated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309: 257–64.
62. Fukumoto S, Matsumoto T, Ikeda K, et al. Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma. Arch Intern Med 1988; 148: 921–5.
63. Stewart AF, Hoecker JL, Mallette LE, Segre GV, Amatruda TT Jr, Vignery A. Hypercalcemia in pheochromocytoma: evidence for a novel mechanism. Ann Intern Med 1985; 102: 776–9.
64. Isales C, Carcangiu ML, Stewart AF. Hypercalcemia in breast cancer: reassessment of the mechanism. Am J Med 1987; 82: 1143–7.
65. Rodan SB. Insogna KL, Vignery AM-C, et al. Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblast cells. J Clin Invest 1983; 72: 1511–5.
66. Klein RF. Strewler GJ, Leung SC, Nissenson RA. Parathyroid hormone–like adenylate cyclase-stimulating activity from a human carcinoma is associated with bone-resorbing activity. Endocrinology 1987; 120: 504–11.
67. Stewart AF. Insogna KL. Burtis WJ, Aminifshar A, Wu T. Broadus AE. Frequency and partial characteristics of adenylate cyclase-stimulating activity in tumors associated with humoral hypercalcemia of malignancy. J Bone Miner Res 1986; 1: 267–76.
68. Weir EC, Insogna KL, Brownstein DG, Bander N, Broadus AE. In vitro adenylate cyclase–stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. J Clin Invest 1988; 81: 818–21.
69. Nissenson RA, Strewler GJ, Williams RD, Leung SC. Activation of the parathyroid hormone receptor-adenylate cyclase system in osteosarcoma cells by a renal carcinoma factor. Cancer Res 1985; 45: 5358–63.
70. Stewart AF, Wu T, Burtis WJ, Weir EC, Broadus AE, Insogna KL. The relative potency of a human tumor-derived PTH-like adenylate cyclase stimulating preparation in three bioassays. J Bone Miner Res 1987; 2: 37–43.
71. Merendino JJ Jr, Insogna KL, Milstone LM, Broadus AE, Stewart AF. A parathyroid hormone–like protein from cultured human keratinocytes. Science 1986; 231: 388–90.
72. Wu TL, Insogna KL, Hough LM, Milstone LM, Stewart AF. Skin-derived fibroblasts respond to human parathyroid hormone–like adenylate cyclasestimulating proteins. J Clin Endocrinol Metab 1987; 65: 105–9.
73. Rabbani SA, Mitchell J, Roy DR, Kremer R, Bennett HP, Goltzman D. Purification of peptide with parathyroid hormone-like bioactivity from human and rat malignancies associated with hypercalcemia. Endocrinology 1986; 118: 1200–10.
74. Stewart AF, Burtis WJ, Wu T, Goumas D, Broadus AE. Two forms of parathyroid hormone-like adenylate cyclase-stimulating protein derived from tumors associated with humoral hypercalcemia of malignancy. J Bone Miner Res 1987; 2: 587–93.
75. Habener JF, Rosenblatt M, Potts JT Jr. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 1984; 64: 985–1053.
76. Ikeda K, Mangin M, Dreyer BE, et al. Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. J Clin Invest 1988; 81: 2010–4.
77. Stewart AF, Mangin M, Wu T, et al. Synthetic human parathyroid hormone–like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 1988; 8: 596–600.
78. Kemp BE, Moseley JM, Rodda CP, et al. Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 1987; 238: 1568–70.
79. Sartori L, Weir EC, Stewart AF, et al. Synthetic and partially-purified adenylate cyclase-stimulating proteins from tumors associated with humoral hypercalcemia of malignancy inhibit phosphate transport in a PTH-responsive renal cell line. J Clin Endocrinol Metab 1988; 66: 459–61.